| Trial ID: | L0159 |
| Source ID: | NCT00890253
|
| Associated Drug: |
Basiliximab (Simulect)
|
| Title: |
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
|
| Acronym: |
CILT
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Liver Transplantation|Chronic Renal Insufficiency
|
| Interventions: |
DRUG: Basiliximab (Simulect)|DRUG: Myfortic|DRUG: everolimus|DRUG: Prednisolone
|
| Outcome Measures: |
Primary: Steroid resistant rejection, 30 days | Secondary: Steroid resistant rejection, 1 year|Liver function, 1 year|Calculated glomerular filtration rate, 1 year|Patient survival, 1 year|Number of days on renal replacement therapy, 1 year|Graft survival, 1 year
|
| Sponsor/Collaborators: |
Sponsor: Armin Goralczyk
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
29
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-01
|
| Completion Date: |
2013-01
|
| Results First Posted: |
|
| Last Update Posted: |
2011-09-15
|
| Locations: |
University Medical Center Goettingen, Goettingen, 37099, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00890253
|
